Immuno-Oncology Resource Center

Immuno-Oncology Resource Center

November 20, 2016
1 min read
Save

Physician–scientist joins NewYork-Presbyterian/Columbia University Medical Center

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

NewYork-Presbyterian/Columbia University Medical Center appointed Charles G. Drake, MD, PhD, as director of genitourinary oncology and associate director for clinical research at Herbert Irving Comprehensive Cancer Center.

Drake, recognized for his understanding of immunotherapy, also will serve as co-director of Columbia’s cancer immunotherapy program, and he will serve on the faculty of Columbia University Medical Center.

Charles G. Drake

“Charles is one of the top minds in immunotherapy and in prostate cancer research and therapies,” Gary Schwartz, MD, chief of the division of hematology/oncology at NewYork-Presbyterian/Columbia University Medical Center and associate director for clinical research at Herbert Irving Comprehensive Cancer Center, said in a press release. “By bringing him on, NewYork-Presbyterian/Columbia is establishing itself as an emerging powerhouse in immunotherapy, which will allow us to unlock the mysteries of our immune system so we can bring new hope to patients with prostate and other genitourinary malignancies.”

Drake previously served as co-director of the cancer immunology program at Johns Hopkins Kimmel Cancer Center.

His work focuses on understanding and fighting advanced-stage cancers with the immune system. His most recent work has focused on the body’s immunological response to radiation therapy, as well as how radiation therapy and immunotherapy can be used together to treat cancer.

“Immunotherapy represents a new frontier in prostate cancer,” Drake said in the press release. “We’re also looking at how it can be used synergistically with traditional therapies, both in prostate cancer as well as in other tumor types.”